carbohydrate counting to determine their mealtime insulin 2, 7 by precisely titrating their insulin dose to their dietary intake, and patients with concomitant Addison's disease, hypopituitarism, chronic kidney disease, or chronic pancreatitis. 2 The Diabetes Control and Complications Trial (DCCT) demonstrated the significance of intensified methods of blood glucose control in T1DM, as this was shown to delay the onset and slow the progression of diabetes-related complications. [8] [9] [10] In TEENs, the largest worldwide study assessing T1DM management in youth aged 8-25 years, optimal glycemic control was only achieved by 28% of participants. 11 Therapy adherence, central to optimal glycemic control, can impart significant treatment burden and worsen the quality of life (QoL) for people with T1DM. 12 Adherence to therapy may be particularly challenging in the pediatric T1DM population, with lower compliance reported compared with adults. 13 Traditionally, insulin has been administered subcutaneously by using a syringe manually filled from a vial. 7 For many patients, this method presents barriers to treatment because of inaccuracy, pain, anxiety, inconvenience and problems with social acceptability. [13] [14] [15] [16] [17] [18] Alternative delivery methods, such as insulin pens, have been designed to help overcome these barriers, [18] [19] [20] [21] and HUPs may be particularly beneficial in achieving therapy adherence and optimal glycemic control in an insulin-sensitive population.
Since the first launch of a half-unit insulin pen (HUP) in 1992, 15 other HUPs have been developed, for example, HumaPen Luxura HD™ (Eli Lilly and Company, Indianapolis, IN, USA; HPL), JuniorSTAR ® (Sanofi, manufactured by Haselmeier, Stuttgart, Germany; JS), NovoPen Echo ® (Novo Nordisk A/S, Bagsvaerd, Denmark; NPE), and NovoPen Junior (Novo Nordisk A/S; NPJ). The different functional characteristics and how these affect user experience and preference are outlined in the "Factors Affecting the User Preference for an HUP" section.
Objective
The objective of this review was to summarize the available literature on functional characteristics of HUPs and their effect on user experience and preferences.
Literature Review Methodology
This systematic review adheres, where relevant, to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement on developing a systematic review. The search was restricted to articles published in English between January 1, 2000, and January 1, 2015. Key search inclusion terms included half-unit insulin pen, halfunit insulin dose, half-unit insulin injection device, glycemic control, diabetes management, injection force, accuracy, patient preference, clinical outcomes, comparison, outcomes, and insulin sensitivity. Additional references not listed on the PubMed database were added if known to the authors and applicable to the review objective. These also included the user guides of HUPs identified through the literature search. Retrieved references were evaluated for suitability. Exclusion criteria included studies not relating to diabetes or insulin delivery devices, those assessing suitability of injection needles, studies of alternative insulin delivery devices, comparison of vial/syringe-pen use and articles describing disposable/prefilled insulin pens or 1U insulin pens. A total of 17 publications met the criteria outlined above and are reviewed in detail below.
Results
The literature was split broadly into 2 categories: (1) functional characteristics of HUPs and (2) factors affecting the user preference for an HUP.
Functional Characteristics of HUPs
This section outlines the main features and technical characterization of HUPs (Table 1) , their accuracy, and injection forces required to perform an injection.
Main Features and Technical Characterization of HUPs
Pen weight, dimensions, and design. The overall size and weight of an insulin pen can greatly affect the convenience of every day transportation and ease of operation. 16 Of the 4 HUPs examined, JS had the lowest weight (Table 1) , NPE was the shortest with the cap on, while JS was the shortest without the cap. 22 The sizes of the dosing display and digits may be of particular significance for populations with impaired visual acuity. 23 HPL had the largest dose display and JS had the largest digits. 22 Dimensions of the injection button will be particularly significant in populations with limited manual dexterity. HPL and JS had the dose buttons of largest dimensions. 22 JS, NPJ, and NPE are also available in multiple colors, which may be beneficial for users who require different insulin variants. Further individualization is offered for the NPE with different skins which may be particularly relevant for the pediatric population. 24 Durability/robustness. Reusable insulin pens are designed to withstand everyday use, and lifetime simulation is required as part of the ISO 11608-1 criteria. 25 Kristensen and Lilleore conducted a study of simulated lifetime use of NPE, which maintained dosing accuracy at all doses throughout the simulated lifetime use test. 26 Clark et al investigated the accuracy of the initial half-unit dose dispensed using the HPL over 3 different temperatures as specified in the ISO 11608 criteria (5°C, room temperature, and 40°C). 27 All delivered doses satisfied the ISO 11608-1 criteria for accuracy of needlebased injection systems. 27 Dialing torque. Dialing torque of an insulin pen refers to the strength needed to adjust the dose-setting dial. 23 Greater ease of use contributes to the confidence a user has in the dose setting and accuracy of a pen, 23 and may be of particular significance in pediatric patients and patients with limited hand strength. Dialing torque has only been reported for JS, where the mean dialing torque for both dialing and correcting a dose was between 5 and 6 N cm. 28 A dialing torque of this magnitude is expected to allow easy dose dialing and correction for pediatric patients. 29 Accuracy. Dose accuracy is vital for maintaining glycemic control and minimizing the risk of complications in people with diabetes. 30, 31 All HUPs have been shown to meet ISO 11608-1 criteria for accuracy of needle-based injection systems, so fluctuations within these criteria are unlikely to be of clinical significance. 26, 27, [31] [32] [33] [34] [35] Injection Force. Injection force is defined as the peak force reached when pushing the injection button during administration of an insulin dose. 20, 36 While not confirmed in a clinical trial, a lower injection force is expected to facilitate simpler operation and reduced injection-site pain. 16, 32, 33, [37] [38] [39] JS had the lowest mean injection force of the HUPs investigated (5.94 N for the flow rate 6.00U/s). 22 All HUPs required a smaller mean injection force than the maximum force that can be exerted on such devices by the pediatric population (>21 N). 29 Therefore all HUPs are suitable for use by this population.
Factors Affecting the User Preference for an HUP
This section summarizes 3 studies examining patient experience in the use of different HUPs (Table 2 ) and outlines how the pen features translate into usability preferences. Olsen et al compared the usability and functionality of NPE, NPJ, and HPL for children and adolescents with T1DM, as well as parents and health care professionals working as diabetes nurse educators or physician/pediatricians. 40 Wong et al conducted a randomized, 2-period, cross-over, open-label study to compare functional usability and preference of HPL and NPJ in 65 adult caregivers of children aged 3-12 years with T1DM. 41 Klonoff et al conducted a noncomparative assessment of JS in 168 HUP users from 5 European countries. 42 Overall Preference. Noncomparative assessment of JS by both pediatric nurses and patients/parents (n = 167) found that the majority agreed JS was easy to use overall, convenient for everyday use and suitable for the lifestyle of a young person with T1DM. 42 When the usability of HPL versus NPJ was tested, the majority of caregivers preferred HPL. 41 Similarly, the majority of participants rated HPL easy/very easy to use, compared with NPE and NPJ. 40 Injection Force. The majority of participants (both pediatric nurses and patients/parents) found the injection force of JS suitable for young people with diabetes. 42 Olsen et al found that more participants using NPE and HPL found the injection force "ideal," compared with users of NPJ (P = .005). 40 Ease of Dose Dialing and Correction. To correct a dose that has been set higher than needed, NPJ requires the barrel and cartridge holder to be separated, followed by pressing the dialup button back to 0, before the pen is assembled again and the correct dose can be dialed. 19, 37 In all other HUPs, an incorrect dose can be corrected by reversing the dial without any insulin loss. 24, 37, 42, 43 Overall, the majority of participants found it easy to dial and to dial back a dose using JS in terms of dial tactility and auditory feedback, and found that these pen features afford flexibility in dialing the correct dose. 42 In terms of ease of correcting a dose, participants preferred HPL to NPJ. 41 Similarly, NPE and HPL were rated better compared with NPJ. 40 The lower preference of NPJ reported in these studies was likely due to the more complex dial-back mechanism compared with other HUPs. The studies indicate that a simple dial-back mechanism that does not waste insulin is preferable.
Ease of Reading Dose/Display. The majority of participants (children/adolescents/parents, 98%; nurses, 94%) rated JS as somewhat good/very good (top 2 options of a 5-point scale) in terms of ease of reading a dose, which may be because of the large dose digit measurement previously reported. 42 The majority of participants also found the dose easy to read when comparing HPL, NPJ, and NPE in a pediatric population. 40 This feature may be of particular significance for patients with sight impairments.
Changing of the Cartridge. Most HUPs require several revolutions to screw the cartridge holder onto the pen with the exception of NPE, which requires a single-movement twist. The majority of study participants (children/adolescents/parents, 83%; nurses, 65%) agreed that JS was somewhat good/ very good for ease of changing the cartridge. 42 In the direct comparison of HPL and NPJ, of the caregivers with a preference, the majority preferred HPL. 41 No usability preference has been reported for NPE. 40 Transportation and Handling. The majority of study participants (children/adolescents/parents, 81%; nurses, 86%) found JS easy to carry on a daily basis, 42 which is important for insulin-sensitive patients who may need to keep the pen on them at all times and monitor insulin requirements regularly. A low weight and smaller size of the pen may be particularly important in light of smaller hands of children as well as for elderly patients with neuromuscular impairments, or hand fatigue. 16, 32, 33, 36, 37, 44 Memory Function. This feature has been developed as a safety feature to address user anxiety over a forgotten dose and risk of hypoglycemia through double-dosing. 14, [45] [46] [47] [48] NPE is the only HUP with this feature and records the last dose volume and time (<12 h). 24, 40, 49 The majority of pediatric users (89%) and parents (94%) rated this feature as very easy or easy to use. 40 The memory function of NPE was also tested in the REMIND study, which included 2-to 18-year-old participants with T1DM. 49 Overall, 83% of participants stated that they used the memory function during the study. 49 Compared with the previously used device, forgotten injections were significantly reduced (51% vs 27%, respectively; P < 0.0001). 49 However, switching from a previous device to an HUP with a memory function was not associated with improved glycemic control. 49, 50 Furthermore, only 42% of health care professionals rated this as a very important feature. 46 
Discussion

Clinical Significance
Inadvertent medication overdoses have been cited as "a common problem among children" by American Academy of Pediatrics. 51 Accuracy to half-unit dose facilitated by HUPs may therefore be particularly significant in the pediatric population and adult patients who are sensitive to insulin. 15, 44 The outlined characteristics and features of the HUPs support a role for HUPs in improved adherence to treatment, 37 leading to improved clinical outcomes and improved QoL. 21, 52 However, no interventional or comparative studies on clinical outcomes (glycemic control) using HUPs were identified in this literature search. Additional studies are required to investigate whether HUP use results in improved glycemic control, and how this feature translates into patient outcomes. Overall, while many of the benefits of HUPs may improve clinical outcomes for young patients with diabetes, real-world studies are required to determine whether this is the case.
Choosing an HUP
Insulin pen characteristics will affect injection procedure and user experience, and may ultimately affect treatment outcome ( Figure 1 ). As insulin pens are manufactured for use with specific insulins, the choice of an insulin pen could also be determined by the insulin prescribed. 44 Since the main objective of using insulin pens is to facilitate optimization of a patient's diabetes management, 53 pen characteristics should be matched with a user's requirements and lifestyle.
The choice of an insulin pen facilitating half-unit versus 1U dosing may be of particular significance to patients with T1DM who are more sensitive to insulin when accuracy at lower doses is crucial, as well as when requiring dose precision and accuracy to a half-unit. Other functional features of HUPs should be matched with user needs and preferences. HUP features affecting dose dialing, correction and dose reading may increase the confidence a user has in dose accuracy. Features facilitating ease and convenience of use, as well as discreetness, could improve treatment flexibility and social acceptance. The main objectives of HUPs are to enable accurate dose delivery to an insulin-sensitive patient, as well as reducing the physical, cognitive and emotional burden of diabetes management. 53 Therefore, all the various features of HUPs and their impact on users' lifestyle should be considered by health care professionals when prescribing insulin.
The most recent development in insulin pens is the development of a "reusable wireless pen" facilitating half-unit increment for mealtime insulin for people with diabetes age 12 years and older, where a Bluetooth connection facilitates transfer of data from the insulin pen to a smartphone app. 54 The app is designed to manage and catalog the insulin dose data, and provide a dose calculator to aid mealtime insulin dose calculations. 54 It is likely that this type of technologic developments represent the future of insulin therapy in this patient population.
In the absence of head-to-head comparison studies across the available HUPs, no conclusion can be drawn on overall user preference.
Beyond Half-Unit Accuracy U20 insulin preparations (20 units/mL) facilitated insulin dosing to 0.2U and were termed "toddler-friendly" insulins because of the small dose increments that could be administered. 55 Since the standardization of U100 insulin preparations (100 units/mL), U20 (20 units/mL) have been withdrawn, leaving a gap in the market for insulin dosing accuracy below 1U. 55 HUPs aid in addressing the lack of small dosing increments by enabling 0.5U dosing increments. Currently, precision and accuracy beyond 0.5U can only be achieved through the use of insulin pumps or by insulin dilution. 55 However, these approaches have drawbacks, because the availability of pumps is limited and insulin dilution necessitates the use of a syringe, 55 introducing the risk of contamination if a patient mixes their own parenteral medications. Pens delivering more accurate insulin dosing with 0.1U precision could benefit certain patient populations, such as insulin-sensitive patients using carbohydrate counting who may only require very low doses of insulin per day.
Conclusions
The development of HUPs has provided improved precision and accuracy of insulin dosing. This feature of HUPs may be relevant to patients requiring lower doses of insulin (eg, pediatric and populations who are sensitive to insulin) as well as others requiring more precise insulin dose adjustments. Currently available HUPs are generally similar in terms of technical characteristics, although some have specific advantageous features and these should be carefully considered for any individual's needs. Although limited, the currently available studies suggest that the selection of an HUP is likely to be influenced by a combination of these aforementioned factors as well as the insulin and dosing regimen prescribed to the user. In summary, HUPs fill a need in insulin dosing and are likely to be a key diabetes management tool for the foreseeable future.
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